Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML

Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML

Dec 06, 2010
Source URL: https://qa1.novartis.us/us-en/news/media-releases/longer-term-phase-iii-data-show-novartis-drug-tasigna-continues-surpass-gleevec-slowing-disease-progression-patients-newly-diagnosed-cml-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/longer-term-phase-iii-data-show-novartis-drug-tasigna-continues-surpass-gleevec-slowing-disease-progression-patients-newly-diagnosed-cml-0